On Veterans Day, a Marine-turned-psychologist explains how advanced brain imaging and data-driven testing are helping vets and clinicians see invisible trauma, measure real change, and open new treatment paths that standard approaches often miss.
The visible wounds of combat are easier to name than the invisible ones, which is why many veterans end up untreated. For years the military and health systems have tried to shrink that gap, yet suicides and untreated post-traumatic stress still claim too many lives. Modern neuroscience is being turned toward closing that divide with tools that can make the unseen visible and measurable.
Dr. Amber Deckard, Psy.D., NPT-C, Director of Neuro-Psychological Services and the Neurocognitive Assessment Program at Caron Treatment Centers, brings a clinician’s rigor and a veteran’s understanding to the work. She served in the Marines from 2003 to 2007 and now focuses on mapping how trauma, concussion and substance use change the brain. Her perspective is shaped by both decades in uniform and years in mental health care.
“Stigma remains one of the biggest barriers,” she said. Many veterans worry that asking for help will be seen as weakness or could jeopardize benefits, and that fear keeps them from care. Deckard argues that objective brain data can reduce shame by reframing symptoms as diagnosable and treatable brain changes rather than moral failings.
The program blends quantitative EEGs, PET scans and neurocognitive testing to chart how different forces alter brain activity and function. “It’s not just, ‘you’re anxious’ or ‘you’re depressed,’” she said. “We can show how the trauma affected the brain and measure improvement over time.”
The stakes are high: in the most recent full year of data, 6,407 suicides were recorded among U.S. veterans, a rate far above that of non-veteran adults. Among those who sought VA care, about 31% had a confirmed mental health diagnosis, signaling large unmet needs and underscoring why better diagnostics matter. Clear, objective findings can push more people toward timely, targeted intervention.
Patients in Deckard’s clinic receive a layered assessment that combines imaging, cognitive testing, a QEEG brain map, full medical and psychiatric evaluations and measures of attention, memory and executive function. “It allows us to get an in-depth, multi-point, objective look at what’s driving their symptoms,” Deckard said. That multi-modal picture helps clinicians tailor treatment rather than relying on one-size-fits-all approaches.
From those assessments, clinicians can recommend neurorestorative options aimed at rewiring or repairing function, including hyperbaric oxygen therapy, alpha-stimulation electrotherapy and transcranial magnetic stimulation. When combined with psychotherapy and rehabilitation, these interventions can target blood flow, electrical activity and cognitive performance. “When individuals have engaged in neurorestorative care, we’ve seen significant improvements across multiple domains,” she said.
Those tools are not yet available uniformly across the VA and health systems, so access depends on location and resources. “We’re not reinventing the wheel,” she said, pointing out that the challenge is integrating existing technologies into cohesive care pathways. Investment, training and system-level coordination will be necessary before advanced neurodiagnostics reach broad clinical use.
For Deckard the central point is about evidence and dignity rather than tech for its own sake. Proof that invisible wounds show up on scans and tests helps remove doubt and open treatment doors. “When they return home, they’re still warriors,” Deckard said. “We just have to give them the tools to fight for their own healing.”
Graduate Student, wife, engaged political and legal writer.